These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 9439509

  • 41. 14-3-3zeta is indispensable for aggregate formation of polyglutamine-expanded huntingtin protein.
    Omi K, Hachiya NS, Tanaka M, Tokunaga K, Kaneko K.
    Neurosci Lett; 2008 Jan 24; 431(1):45-50. PubMed ID: 18078716
    [Abstract] [Full Text] [Related]

  • 42. Transgenic models of Huntington's disease.
    Bates GP, Mangiarini L, Mahal A, Davies SW.
    Hum Mol Genet; 1997 Jan 24; 6(10):1633-7. PubMed ID: 9300654
    [Abstract] [Full Text] [Related]

  • 43. Huntington's disease: a clinical, genetic and molecular model for polyglutamine repeat disorders.
    Harper PS.
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun 29; 354(1386):957-61. PubMed ID: 10434293
    [No Abstract] [Full Text] [Related]

  • 44. Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons.
    Jackson GR, Salecker I, Dong X, Yao X, Arnheim N, Faber PW, MacDonald ME, Zipursky SL.
    Neuron; 1998 Sep 29; 21(3):633-42. PubMed ID: 9768849
    [Abstract] [Full Text] [Related]

  • 45. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length.
    de Almeida LP, Ross CA, Zala D, Aebischer P, Déglon N.
    J Neurosci; 2002 May 01; 22(9):3473-83. PubMed ID: 11978824
    [Abstract] [Full Text] [Related]

  • 46. Neurological abnormalities in a knock-in mouse model of Huntington's disease.
    Lin CH, Tallaksen-Greene S, Chien WM, Cearley JA, Jackson WS, Crouse AB, Ren S, Li XJ, Albin RL, Detloff PJ.
    Hum Mol Genet; 2001 Jan 15; 10(2):137-44. PubMed ID: 11152661
    [Abstract] [Full Text] [Related]

  • 47. Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies.
    Jimenez-Sanchez M, Licitra F, Underwood BR, Rubinsztein DC.
    Cold Spring Harb Perspect Med; 2017 Jul 05; 7(7):. PubMed ID: 27940602
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Huntington's disease: translating a CAG repeat into a pathogenic mechanism.
    MacDonald ME, Gusella JF.
    Curr Opin Neurobiol; 1996 Oct 05; 6(5):638-43. PubMed ID: 8937828
    [Abstract] [Full Text] [Related]

  • 50. Huntington's disease (HD): degeneration of select nuclei, widespread occurrence of neuronal nuclear and axonal inclusions in the brainstem.
    Rüb U, Hentschel M, Stratmann K, Brunt E, Heinsen H, Seidel K, Bouzrou M, Auburger G, Paulson H, Vonsattel JP, Lange H, Korf HW, den Dunnen W.
    Brain Pathol; 2014 Apr 05; 24(3):247-60. PubMed ID: 24779419
    [Abstract] [Full Text] [Related]

  • 51. Pathological mechanisms in Huntington's disease and other polyglutamine expansion diseases.
    Lunkes A, Trottier Y, Mandel JL.
    Essays Biochem; 1998 Apr 05; 33():149-63. PubMed ID: 10488448
    [Abstract] [Full Text] [Related]

  • 52. The selective vulnerability of nerve cells in Huntington's disease.
    Sieradzan KA, Mann DM.
    Neuropathol Appl Neurobiol; 2001 Feb 05; 27(1):1-21. PubMed ID: 11298997
    [Abstract] [Full Text] [Related]

  • 53. Promyelocytic leukemia protein is redistributed during the formation of intranuclear inclusions independent of polyglutamine expansion: an immunohistochemical study on Marinesco bodies.
    Kumada S, Uchihara T, Hayashi M, Nakamura A, Kikuchi E, Mizutani T, Oda M.
    J Neuropathol Exp Neurol; 2002 Nov 05; 61(11):984-91. PubMed ID: 12430715
    [Abstract] [Full Text] [Related]

  • 54. In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington's disease.
    Panov AV, Burke JR, Strittmatter WJ, Greenamyre JT.
    Arch Biochem Biophys; 2003 Feb 01; 410(1):1-6. PubMed ID: 12559971
    [Abstract] [Full Text] [Related]

  • 55. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions.
    Slow EJ, Graham RK, Osmand AP, Devon RS, Lu G, Deng Y, Pearson J, Vaid K, Bissada N, Wetzel R, Leavitt BR, Hayden MR.
    Proc Natl Acad Sci U S A; 2005 Aug 09; 102(32):11402-7. PubMed ID: 16076956
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.